MGX (STOCKS)
Metagenomi Therapeutics, Inc. Common Stock
$1.400000
+0.020000 (+1.45%)
Prev close: $1.380000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jian Irish
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $52.67M
- Employees
- 171
- P/E (TTM)
- -0.59
- P/B (TTM)
- 0.33
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.60 | $-0.61 | +0.0115 | +1.88% |
|
Sep 2025 (Q3)
|
$-0.55 | $-0.59 | +0.0398 | +6.75% |
|
Jun 2025 (Q2)
|
$-0.54 | $-0.63 | +0.0872 | +13.90% |
|
Mar 2025 (Q1)
|
$-0.68 | $-0.58 | -0.0962 | -16.48% |
Financial Statements
| Revenues | $25.21M |
| Benefits Costs and Expenses | $113.14M |
| Costs And Expenses | $113.14M |
| Nonoperating Income/Loss | $8.09M |
| Operating Expenses | $121.22M |
| Research and Development | $94.43M |
| Other Operating Expenses | $26.79M |
| Operating Income/Loss | -$96.01M |
| Income/Loss From Continuing Operations After Tax | -$87.87M |
| Income/Loss From Continuing Operations Before Tax | -$87.93M |
| Income Tax Expense/Benefit | -$58.00K |
| Income Tax Expense/Benefit, Current | -$58.00K |
| Net Income/Loss | -$87.87M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$87.87M |
| Net Income/Loss Available To Common Stockholders, Basic | -$87.87M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.36 |
| Diluted Earnings Per Share | -$2.36 |
| Basic Average Shares | 37,251,050 |
| Diluted Average Shares | 37,251,050 |
| Assets | $221.10M |
| Current Assets | $165.54M |
| Cash | $160.80M |
| Accounts Receivable | $305.00K |
| Other Current Assets | $4.43M |
| Noncurrent Assets | $55.57M |
| Fixed Assets | $12.29M |
| Other Non-current Assets | $43.28M |
| Liabilities | $62.51M |
| Current Liabilities | $22.93M |
| Accounts Payable | $1.49M |
| Other Current Liabilities | $21.44M |
| Noncurrent Liabilities | $39.57M |
| Equity | $158.60M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $158.60M |
| Liabilities And Equity | $221.10M |
| Net Cash Flow From Operating Activities | -$88.89M |
| Net Cash Flow From Operating Activities, Continuing | -$88.89M |
| Net Cash Flow From Investing Activities | $103.53M |
| Net Cash Flow From Investing Activities, Continuing | $103.53M |
| Net Cash Flow From Financing Activities | -$356.00K |
| Net Cash Flow From Financing Activities, Continuing | -$356.00K |
| Net Cash Flow | $14.28M |
| Net Cash Flow, Continuing | $14.28M |
| Comprehensive Income/Loss | -$88.32M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$88.32M |
| Other Comprehensive Income/Loss | -$449.00K |
| Other Comprehensive Income/Loss Attributable To Parent | -$449.00K |